Full-Time

Associate Principal Scientist

Imaging

Confirmed live in the last 24 hours

Deadline 6/30/25
Merck

Merck

10,001+ employees

Develops medicines and vaccines for health issues

No salary listed

Senior, Expert

H1B Sponsorship Available

North Wales, PA, USA

Hybrid work model consisting of three total days on-site per week, Monday - Thursday, with Friday designated as a remote-working day.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • Master's (with 8+ years) or Ph.D. (with 4+ years) in biology, pharmacology, radiopharmaceutical sciences or related field and relevant work experience in the area of radiopharmaceutical discovery
  • Design, optimization, and implementation of radioligand binding experiments in tissue homogenate
  • Design, optimization, and implementation of autoradiography experiments on tissue slices
  • Sectioning of frozen tissue for autoradiography experiments
  • Ability to independently design, execute and interpret in vitro radioligand binding experiments
  • Analysis and interpretation of data from in vitro binding experiments using graphical nonlinear curve fitting software methods
  • Theoretical knowledge of ligand-receptor binding interactions and their application to drug discovery
  • Proven track record of generating publication quality data and contributing to manuscript or patent preparation
  • Highly developed oral and written communication skills and keen ability to engage internal and external team members in collaborative research
  • Self-motivated and resourceful with good interpersonal skills
  • Ability to independently manage workflow to see projects through from start to completion
  • Strong interpersonal, verbal and written communication skills
  • Willingness and ability to work with radioactive materials including ³H, 18F, and/or 89Zr
  • Strong record keeping skills
  • Demonstrates a high level of attention to detail
Responsibilities
  • Design, optimize and perform in vitro radioligand binding assays, including autoradiography and tissue homogenate binding assays, to assess the binding characteristics of radioligands to support PET tracer discovery and development
  • Analyze, interpret results and draw conclusions from experiments, and suggest, design, and pursue relevant experiments
  • Generate reliable and reproducible data in a timely manner
  • Present results and next steps at group meetings and project meetings
  • Access and understand relevant scientific literature and apply theoretical framework to solving problems within scientific discipline in a timely manner
  • Work effectively with other scientists as part of a collaborative, multidisciplinary team
Desired Qualifications
  • Experience with molecular biology assays such as Western blot, ELISA, etc.
  • Immunohistochemistry and/or immunofluorescence staining experience

Merck develops medicines and vaccines to address major health challenges such as cardiovascular disease, diabetes, and cancer. The company conducts extensive research and development to create new treatments, focusing on the pharmaceutical and biotechnology sectors. Merck generates revenue through the sale of prescription medications, vaccines, and animal health products. A key aspect of Merck's approach is its commitment to patient assistance programs, which provide free medicines and vaccines to eligible patients. Additionally, Merck supports healthcare professionals with resources like Merck Connect and Merck Manuals, setting it apart from competitors by emphasizing both patient care and professional education.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck's $1 billion investment in a vaccine site boosts U.S. manufacturing capabilities.
  • AI-driven drug discovery platforms improve R&D efficiency and success rates.
  • Digital twins in clinical trials enhance trial designs and personalized medicine approaches.

What critics are saying

  • Merck's mumps vaccine fraud damages reputation and trust in vaccine products.
  • Susonity cosmetics brand may divert focus from core pharmaceutical operations.
  • U.S. manufacturing expansion faces financial risks from changing market conditions.

What makes Merck unique

  • Merck's collaboration with Benchling enhances bioanalytical workflows for vaccine development.
  • Merck's AI initiatives accelerate R&D and reduce software development costs.
  • Merck's investment in mRNA technology opens new treatment avenues beyond vaccines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Holidays

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Flexible Work Hours

Company News

Yahoo Finance
Jun 11th, 2025
Benchling Announces Collaboration With Merck On Vaccine Bioanalysis

Unified platform drives bioanalytical capacity, throughput, and efficiency in regulated environment SAN FRANCISCO, June 11, 2025 /PRNewswire/ -- Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a software framework that helps bring Merck's pre-clinical and clinical bioanalytical workflows onto one flexible, fully integrated platform. The collaboration focuses on three key areas: enhancing speed and throughput with automated data capture and integration; streamlining with a unified platform for managing workflows and data across the bioanalytical lifecycle; and maintaining rigorous quality and compliance standards in a regulated bioanalytical setting. "Our work with Merck demonstrates how technology and thoughtful collaboration can help address key scientific needs in bioanalysis," said Sajith Wickramasekara, co-founder and CEO of Benchling. "By focusing on the modern demands of bioanalytical labs, we're delivering an approach that aims to enhance efficiency throughout the vaccine development lifecycle." "Sophisticated data management capabilities are integral to advancing vaccine research and development," said Roy Helmy, Associate Vice President, Regulated Bioanalytics at Merck Research Laboratories. "We're thrilled to collaborate with the team at Benchling on a digital integration that enables our scientists to access, analyze, and harness data insights throughout the development process." About Benchling Benchling creates the software that powers the biotechnology industry, serving cutting-edge start-ups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling RD Cloud as their central source of truth for scientific data, analysis, and collaboration

News Channel Nebraska
Jun 4th, 2025
AI Networking Summit Dallas 2025 Breaks Records and Sets the Stage for the Future of AI-Powered Enterprises

Merck's Sean Finnerty was awarded a Community Appreciation Award for sharing how Merck is using AI to speed up and save software development costs.

Personal Care Magazine
May 30th, 2025
Merck reveals launch of Susonity brand for cosmetics

Merck reveals launch of Susonity brand for cosmetics.

MyCentralJersey
May 29th, 2025
NJ drug companies will spend billions to expand in the U.S. Here's what's driving them

Rahway-based drugmaker Merck last month announced plans to spend $1 billion on a vaccine manufacturing site in North Carolina, plus $8 billion on other upgrades by 2028.

Natural News
May 22nd, 2025
Merck's mumps fraud: A 50-year cover-up exposed as vaccine efficacy claims crumble

Merck's mumps vaccine, part of the MMR shots, is confirmed to be far less effective than claimed, with courts acknowledging intentional fraud to maintain monopoly and avoid admitting failure.